Login / Signup
Retraction Note: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
Boya Zhang
Mingpeng Zhang
Yanjie Yang
Qi Li
Jianpeng Yu
Shimiao Zhu
Yuanjie Niu
Zhiqun Shang
Published in:
Oncogene (2023)
Keyphrases
</>
prostate cancer
cancer therapy